Literature DB >> 20119858

Sacral neuromodulation and cardiac pacemakers.

Ted M Roth1.   

Abstract

INTRODUCTION AND HYPOTHESIS: Potential for cross-talk between cardiac pacemakers and sacral neuromodulation remains speculative.
METHODS: We present a case series of patients with cardiac pacemakers who underwent staged Interstim (Medtronic, Minneapolis, MN) implantation and patients who had pulse generator implantation who later required cardiac pacemakers.
RESULTS: No cross-talk was demonstrated in either group.
CONCLUSIONS: Sacral neuromodulation appears to be safe in the setting of cardiac pacemakers without cardioversion/defibrillation technology.

Entities:  

Mesh:

Year:  2010        PMID: 20119858     DOI: 10.1007/s00192-009-1091-7

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  4 in total

1.  Interference in pacemakers.

Authors:  W Irnich
Journal:  Pacing Clin Electrophysiol       Date:  1984-11       Impact factor: 1.976

2.  Management of spinal cord stimulators in patients with cardiac pacemakers.

Authors:  C Andersen; H Oxhøj; P Arnsbo
Journal:  Pacing Clin Electrophysiol       Date:  1990-05       Impact factor: 1.976

3.  Management of cardiac pacemaker in a patient with spinal cord stimulator implant.

Authors:  R Iyer; T V Gnanadurai; P Forsey
Journal:  Pain       Date:  1998-02       Impact factor: 6.961

4.  Sacral nerve neuromodulation in patients with cardiac pacemakers.

Authors:  Patricia A Wallace; Felicia L Lane; Karen L Noblett
Journal:  Am J Obstet Gynecol       Date:  2007-07       Impact factor: 8.661

  4 in total
  2 in total

1.  Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery.

Authors:  Ngoc-Bich Le; Ja-Hong Kim
Journal:  Curr Bladder Dysfunct Rep       Date:  2010-11-25

2.  Sacral Neuromodulation in Patients With a Cardiac Pacemaker.

Authors:  Abdullah A Gahzi; Dean S Elterman; Magdy Hassouna
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.